Abstract:Atopic dermatitis is a chronic inflammatory skin disease. Patients with atopic dermatitis experience inflammatory lesions associated with intense itch and pain, which lead to sleep disturbance and poor mental health and quality of life. We review the molecular mechanisms underlying itch and pain symptoms in atopic dermatitis and discuss the current clinical development of treatments for moderate-to-severe atopic dermatitis. The molecular pathology of atopic dermatitis includes aberrant immune activation involving significant cross-talk among the skin and immune and neuronal cells. Exogenous and endogenous triggers modulate stimulation of mediators including cytokine/chemokine expression/release by the skin and immune cells, which causes inflammation, skin barrier disruption, activation and growth of sensory neurons, itch and pain. These complex interactions among cell types are mediated primarily by cytokines, but also involve chemokines, neurotransmitters, lipids, proteases, antimicrobial peptides, agonists of ion channels or various G protein-coupled receptors. Patients with atopic dermatitis have a cytokine profile characterised by abnormal levels of interleukins 4, 12, 13, 18, 22, 31 and 33; thymic stromal lymphopoietin; and interferon gamma. Cytokine receptors mainly signal through the Janus kinase/signal transducer and activator of transcription pathway. Among emerging novel therapeutics, several Janus kinase inhibitors are being developed for topical or systemic treatment of moderate-to-severe atopic dermatitis because of their potential to modulate cytokine expression and release. Janus kinase inhibitors lead to changes in gene expression that have favourable effects on local and systemic cytokine release, and probably other mediators, thus successfully modulating molecular mechanisms responsible for itch and pain in atopic dermatitis.

Cytokines and Chemokines Modulation of Itch

Molecular and cellular mechanisms of itch sensation and the anti-itch drug targets

Inflammatory mediators causing cutaneous chronic itch in some diseases via transient receptor potential channel subfamily V member 1 and subfamily A member 1

Molecular and cellular pruritus mechanisms in the host skin

Keratinocyte TLR2 and TLR7 contribute to chronic itch through pruritic cytokines and chemokines in mice

Mechanism of Skin-Derived Itch

Molecular Mechanisms of Pruritus in Prurigo Nodularis

Itch: From mechanism to (novel) therapeutic approaches

IL-33/ST2 signaling in the pathogenesis of chronic pain and itch

The Cytokine TGF-β Induces Interleukin-31 Expression from Dermal Dendritic Cells to Activate Sensory Neurons and Stimulate Wound Itching

CXCR3 chemokine receptor signaling mediates itch in experimental allergic contact dermatitis

TLR3 Deficiency Impairs Spinal Cord Synaptic Transmission, Central Sensitization, and Pruritus in Mice.

Common and discrete mechanisms underlying chronic pain and itch: peripheral and central sensitization

A basophil-neuronal axis promotes itch

Itch-Relieving Cosmetics

Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas

Altered expression of target genes of spinal cord in different itch models compared with capsaicin assessed by RT-qPCR validation

Neuronal BST2: A Pruritic Mediator Alongside PAR2 in the Interleukin-27-Driven Itch Pathway

Mechanical and chemical itch regulated by neuropeptide Y-Y1 signaling

Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics

Interleukin Profiling in Atopic Dermatitis and Chronic Nodular Prurigo